Showing results (191-200 of 662) with videos related to
Sort By:
Pageof 67
Radiology|January 1, 1977
Comparison of I-bleomycin prepared by two methods stability and pharmacokinetics in tumor-bearing miceK A Krohn, J Meyers, G L DeNardoJournal for Immunotherapy of Cancer|January 20, 2021
Rethinking immune checkpoint blockade: 'Beyond the T cell'Xiuting Liu, Graham D Hogg, David G DeNardoImmunological Reviews|March 28, 2008
Polarized immune responses differentially regulate cancer developmentMagnus Johansson, David G Denardo, Lisa M CoussensNeurobiology of Learning and Memory|March 3, 2025
Developmental changes in brain-wide fear memory networksBenita Jin, Michael W Gongwer, Laura A DeNardoCancer|February 1, 1994
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugatesD L Kukis, H Diril, D P Greiner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignanciesK R Lamborn, G L DeNardo, S J DeNardo, et al.Anticancer Research|May 1, 1997
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibodyS J Denardo, L F O'Grady, C M Richman, et al.Cancer Research|April 1, 1989
Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in miceG P Adams, S J DeNardo, S V Deshpande, et al.Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenograftsR T O'Donnell, S J DeNardo, L A Miers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapySally J DeNardo, Gerald L DeNardo, Laird A Miers, et al.Pageof 67